Award Presented at ICAD Meeting July 27, 2008

Vernon Hills, IL July 28, 2008 –Applied NeuroSolutions, Inc. (OTC BB:APNS, www.AppliedNeuroSolutions.com), a biotechnology Company focused on the development of products for the early diagnosis and treatment of Alzheimer’s disease (“AD”), today announced its’ founding scientist, Dr. Peter Davies, was presented with The Khalid Iqbal and Bengt Winblad Lifetime Achievement Award in Alzheimer’s disease research at the Alzheimer’s Association’s 11th International Conference on Alzheimer’s Disease (“ICAD”) in Chicago.  The Association presents this award to outstanding scientists who have dedicated themselves to helping millions around the world through their research.

Dr. Davies is currently a Professor in the Departments of Pathology and Neuroscience at Albert Einstein College of Medicine (“AECOM”), where he holds the Judith and Burton P. Resnick Chair for research on Alzheimer’s Disease.  Dr. Davies also serves as the Scientific Director of the Litwin/Zucker Center for Research on Alzheimer’s Disease at the Feinstein Institute for Medical Research, North Shore/LIJ.  For more than 30 years, Dr. Davies’ research has focused on the biochemistry of Alzheimer's disease. He has published over 200 research papers, and is one of only a handful of investigators in the USA who have received two MERIT awards from the National Institutes of Health (NIMH, 1989-1999, and NIA 2003-2013). These awards are given to “selected investigators who have demonstrated superior competence and outstanding productivity”, and provide up to 10 years of continuous research support.

William H. Thies, Ph.D., Vice President of Medical and Scientific Relations for the Alzheimer’s Association noted, “We are very pleased to recognize and honor the accomplishments of Dr. Davies.  His lifetime of work in the field of Alzheimer’s disease is at the forefront of novel research that we hope will lead to very promising diagnostics and treatments for the millions of people with Alzheimer’s.”

Dr. Davies has been associated with Applied NeuroSolutions since the company was founded and continues to work with the Company’s scientists in the development of tau-based diagnostic tests for Alzheimer’s disease.  As a result of Dr. Davies’ research and the Company’s expertise, APNS entered into a collaboration agreement with Eli Lilly and Company (in November 2006) to develop therapeutics to treat AD.

Commenting on the announcement of the award, Ellen R. Hoffing, APNS’s Chairman, President and Chief Executive Officer, stated “Dr. Davies has clearly demonstrated during his 30+ years of research a focused commitment, yielding exciting advancements for AD solutions, for which he is most deserving of this prestigious award. Dr. Davies’ novel tau-based discoveries, coupled with his enthusiasm and creativity, provide key elements for the Applied NeuroSolutions’ team to continue to advance the important goals of developing biomarkers to aid in the early diagnosis as well as effective treatments for AD.”

For further information please visit the company's website at www.AppliedNeuroSolutions.com, and review the company's filings with the Securities and Exchange Commission.

About Applied NeuroSolutions:

Applied NeuroSolutions, Inc. (OTC BB:APNS - News) is developing diagnostics and therapeutics to detect and treat Alzheimer's disease (AD) building on discoveries originating from the Albert Einstein College of Medicine.  Applied NeuroSolutions is in a collaboration with Eli Lilly and Company to develop novel therapeutic compounds to treat the progression of AD.  For the diagnostic pipeline, Applied NeuroSolutions is focused on both cerebrospinal fluid (CSF) and serum tests to detect AD at a very early stage.  The P-Tau 231 test now being offered for use in clinical trials can effectively differentiate AD patients from those with other neurological diseases that have similar symptoms. There is currently no FDA approved diagnostic test to detect AD. Alzheimer's disease currently afflicts over five million Americans, and the world market for AD therapy is currently estimated to be 30 million patients.  For more information, visit www.AppliedNeuroSolutions.com

This press release contains forward-looking statements about Applied NeuroSolutions. The company wishes to caution the readers of this press release that actual results may differ from those discussed in the forward-looking statements and may be adversely affected by, among other things, the risks associated with new product development and commercialization, clinical trials, intellectual property, regulatory approvals, potential competitive offerings, and access to capital. For further information, please visit the company's website at www.AppliedNeuroSolutions.com, and review the company's filings with the Securities and Exchange Commission.

Contact:
Applied NeuroSolutions: 847-573-8000
Ellen Hoffing, Chairman, President & CEO
David Ellison, CFO